Shanghai-based biopharmaceutical company, Dizal, has published new Pivotal Phase II Trial Data on sunvozertinib in non-small cell lung cancer (NSCLC). Sunvozertinib is an oral and selective tyrosine kinase inhibitor that has a favorable encouraging anti tumor activity, as shown in Phase 1 studies of patients with non-small cell lung cancer. It is discovered by Dizal